KALA BIO, Inc.
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical d… Read more
KALA BIO, Inc. (0JQ2) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 1.255x
Based on the latest financial reports, KALA BIO, Inc. (0JQ2) has a cash flow conversion efficiency ratio of 1.255x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.88 Million) by net assets ($-8.66 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
KALA BIO, Inc. - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how KALA BIO, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
KALA BIO, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of KALA BIO, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GHST World Inc
PINK:GHST
|
0.072x |
|
Birks Group Inc
NYSE MKT:BGI
|
0.195x |
|
Trillium Gold Mines Inc
OTCQX:TGLDF
|
-0.026x |
|
Verena Multi Finance Tbk
JK:VRNA
|
0.085x |
|
Monumental Minerals Corp
OTCQB:MNMRF
|
-0.196x |
|
REPUBLIC SERVICES - Dusseldorf Stock Exchang
DU:RPU
|
0.089x |
|
HOUSTON AMERN ENE.DL-001
F:8H6H
|
N/A |
|
American Copper Development Corporation
OTCQB:ACDXF
|
-0.557x |
Annual Cash Flow Conversion Efficiency for KALA BIO, Inc. (2013–2024)
The table below shows the annual cash flow conversion efficiency of KALA BIO, Inc. from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $12.33 Million | $-29.38 Million | -2.383x | +35.98% |
| 2023-12-31 | $7.50 Million | $-27.93 Million | -3.722x | +10.51% |
| 2022-12-31 | $18.97 Million | $-78.91 Million | -4.159x | +35.43% |
| 2021-12-31 | $16.80 Million | $-108.23 Million | -6.441x | -610.16% |
| 2020-12-31 | $100.00 Million | $-90.69 Million | -0.907x | +70.96% |
| 2019-12-31 | $29.69 Million | $-92.72 Million | -3.123x | -505.76% |
| 2018-12-31 | $104.99 Million | $-54.12 Million | -0.516x | -35.58% |
| 2017-12-31 | $89.68 Million | $-34.10 Million | -0.380x | -222.02% |
| 2016-12-31 | $-87.76 Million | $-27.35 Million | 0.312x | -88.04% |
| 2015-12-31 | $-5.79 Million | $-15.09 Million | 2.605x | +155.31% |
| 2014-12-31 | $3.26 Million | $-15.36 Million | -4.709x | +91.23% |
| 2013-12-31 | $202.00K | $-10.84 Million | -53.673x | -- |